Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey.
| Title: | Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey. |
|---|---|
| Authors: | Doane MJ; Alkermes, Inc, Waltham, MA, USA.; Sajatovic M; University Hospitals Cleveland Medical Center, Cleveland, OH, USA.; Weiden PJ; Alkermes, Inc, Waltham, MA, USA.; O'Sullivan AK; Alkermes, Inc, Waltham, MA, USA.; Maher S; Optum, Patient Insights, Johnston, RI, USA.; Bjorner JB; Optum, Patient Insights, Johnston, RI, USA.; Sikora Kessler A; Optum, Patient Insights, Johnston, RI, USA.; Carpenter-Conlin J; Alkermes, Inc, Waltham, MA, USA.; Bessonova L; Alkermes, Inc, Waltham, MA, USA.; Velligan DI; The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. |
| Source: | Patient preference and adherence [Patient Prefer Adherence] 2020 Oct 28; Vol. 14, pp. 2043-2054. Date of Electronic Publication: 2020 Oct 28 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475748 Publication Model: eCollection Cited Medium: Print ISSN: 1177-889X (Print) Linking ISSN: 1177889X NLM ISO Abbreviation: Patient Prefer Adherence Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Auckland, N.Z.] : Dove Press Limited |
| Abstract: | Background: This survey examined the experiences of people living with schizophrenia who have used oral antipsychotics (APs).; Methods: Adults with self-reported physician-diagnosed schizophrenia (N=200), who were members of an online research participation panel and reported taking one or more oral APs within the last year, completed a cross-sectional online survey that focused on direct report of their experiences regarding APs (eg, symptoms, side effects, adherence). Descriptive analyses were conducted for the total survey sample and for subgroups defined a priori by experience with specific, prevalent side effects.; Results: The mean age of the sample was 41.9 (SD=11.0) years, 50% of participants were female, and 32% were nonwhite. Overall ratings were positive for medication effectiveness and convenience but negative for side effects. While most participants reported that APs improved schizophrenia symptoms (92%), 27% reported APs as having done "more harm than good." Almost all participants (98%) reported experiencing side effects of APs, with the most common being anxiety (88%), feeling drowsy/tired (86%), and trouble concentrating (85%). Side effects frequently cited as either "extremely" or "very" bothersome were weight gain (56%), sexual dysfunction (55%), and trouble concentrating (54%). Over 80% reported that side effects had negatively impacted their work and social functioning (eg, social activities or family/romantic relationships). Since initiating treatment, 56% of respondents had stopped taking APs at some point (65% of these due to side effects). Side effects commonly reported as having led to stopping AP treatment were "feeling like a 'zombie'" (22%), feeling drowsy/tired (21%), and weight gain (20%).; Conclusion: Most participants reported improvements in schizophrenia symptoms associated with the use of APs. However, most participants also reported experiencing numerous bothersome side effects that negatively impacted their work, social functioning, and treatment adherence. Results highlight the unmet need for new APs with favorable benefit-risk profiles.; (© 2020 Doane et al.) |
| Competing Interests: | MJD, AKO, and LB are employees of Alkermes, Inc. and own stock in the company. PJW and JCC were employees of Alkermes, Inc. at the time the study was conducted. SM, ASK, and JBB are employees of Optum, Inc., which was paid by Alkermes, Inc. for assistance in designing and conducting this study, performing statistical analysis, and developing this manuscript. MS reports grants from Nuromate, Otsuka, Alkermes, International Society for Bipolar Disorders (ISBD), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Patient-Centered Outcomes Research Institute (PCORI), personal fees from Alkermes, Otsuka, Janssen, Neurocrine, Bracket, Health Analytics, Frontline Medical Communications, publication royalties from Springer Press, Johns Hopkins University Press, Oxford Press, UpToDate, personal fees from American Physician’s Institute, MCM Education, CMEology, Potomac Center for Medical Education, Global Medical Education, Creative Educational Concepts, and Psychopharmacology Institute, during the conduct of the study. DIV reports personal fees from Janssen, Otsuka, Alkermes, Lundbeck, during the conduct of the study. The authors report no other conflicts of interest in this work. |
| References: | Patient Prefer Adherence. 2013 Nov 13;7:1171-80. (PMID: 24265549); Front Neurosci. 2015 Sep 03;9:297. (PMID: 26388714); Psychiatry Res. 2006 Nov 15;144(2-3):177-89. (PMID: 17010448); Psychiatry Res. 2003 Feb 15;117(2):103-12. (PMID: 12606013); Ann Intern Med. 1978 Feb;88(2):251-8. (PMID: 626456); Arch Gen Psychiatry. 1999 Mar;56(3):241-7. (PMID: 10078501); Br J Psychiatry. 2005 Dec;187:529-36. (PMID: 16319405); Eur Psychiatry. 2005 Aug;20(5-6):395-402. (PMID: 16171654); Curr Neuropharmacol. 2017;15(5):789-798. (PMID: 27928948); J Nerv Ment Dis. 1994 Jan;182(1):50-4. (PMID: 8277302); J Clin Psychiatry. 2016 Jun;77(6):764-71. (PMID: 27135986); J Sex Marital Ther. 2003 Mar-Apr;29(2):125-47. (PMID: 12623765); N Engl J Med. 2005 Sep 22;353(12):1209-23. (PMID: 16172203); Value Health. 2005 Nov-Dec;8 Suppl 1:S9-S24. (PMID: 16336491); Int J Soc Psychiatry. 2016 Feb;62(1):12-20. (PMID: 25987581); Nat Sci Sleep. 2017 Sep 21;9:227-239. (PMID: 29033618); Schizophr Bull. 2006 Oct;32(4):786-94. (PMID: 16887889); Schizophr Res. 2012 May;137(1-3):203-11. (PMID: 22341200); Curr Med Chem. 2004 Feb;11(3):343-58. (PMID: 14965236); Psychiatry Res. 2015 Feb 28;225(3):458-63. (PMID: 25563669); Am J Psychiatry. 2009 Feb;166(2):152-63. (PMID: 19015230); J Clin Psychiatry. 2004 Sep;65(9):1211-8. (PMID: 15367047); J Clin Psychiatry. 2008 Jan;69(1):47-53. (PMID: 18312037); Psychiatr Danub. 2017 Mar;29(1):60-65. (PMID: 28291975); Psychiatr Serv. 2015 Jul;66(7):719-26. (PMID: 25772762); Psychiatr Serv. 2002 Oct;53(10):1319-21. (PMID: 12364685); Neuropsychiatr Dis Treat. 2016 Feb 16;12:357-73. (PMID: 26937191); Eur Psychiatry. 2004 Nov;19(7):415-22. (PMID: 15504648); Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56. (PMID: 15000267); Patient Prefer Adherence. 2018 Jan 04;12:63-70. (PMID: 29379273); Arch Gen Psychiatry. 2003 Jun;60(6):565-71. (PMID: 12796219); J Clin Psychiatry. 2004 Jul;65(7):932-9. (PMID: 15291682); Curr Psychiatry Rep. 2012 Jun;14(3):229-36. (PMID: 22477360); Qual Life Res. 2019 Dec;28(12):3303-3312. (PMID: 31435866); Health Qual Life Outcomes. 2006 Oct 11;4:79. (PMID: 17034633); J Psychosom Res. 2017 Sep;100:35-45. (PMID: 28789791); Mol Psychiatry. 2008 Jan;13(1):27-35. (PMID: 17848919); J Med Econ. 2019 Nov;22(11):1105-1112. (PMID: 31062998); J Med Econ. 2018 Feb;21(2):127-134. (PMID: 28895758) |
| Contributed Indexing: | Keywords: adherence; antipsychotics; efficacy; preference; schizophrenia; side effects |
| Entry Date(s): | Date Created: 20201105 Latest Revision: 20220418 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7604247 |
| DOI: | 10.2147/PPA.S270020 |
| PMID: | 33149559 |
| Database: | MEDLINE |
Journal Article